Peptide FDA and HHS Status Tracker

US legal status of 27 peptide entries people search for, from BPC-157 to retatrutide, as of Oct 29, 2026: FDA approval, 503A bulk drug substance category, Pharmacy Compounding Advisory Committee votes, FDA-approved products, WADA Prohibited List status and the next regulatory step, each with dates and source URLs. The file flags the six peptides named in the draft HHS "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" filed Oct 28, 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496): BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, with the form and routes Appendix B of the draft names for each. The draft is enforcement discretion, not FDA approval, and is not final. Of the 27 entries: 6 have a legal route (3 FDA-approved drugs, 2 compoundable with a prescription, 1 topical only), 6 are in the draft HHS policy, 5 are under FDA review, 9 are not allowed in compounding or are in trials only, and 1 is not confirmed. One CSV (21 columns, UTF-8, ISO 8601 dates, true/false flags) and a README data dictionary. Updated when Wellchosen Health rechecks a source or fixes an error; there is no fixed schedule. Cite as: Wellchosen Health (2026). Peptide FDA and HHS Status Tracker [Data set]. https://wellchosenhealth.com/peptides/